Figure 5.

Pioglitazone activation of PPARγ reduces CML burden in Se-A mice. Pioglitazone (5 mg/kg) was given to Se-A mice by i.p. injection daily starting 1 day prior to BCR-ABL transplant, until euthanized. The same duration of treatment was given for healthy pioglitazone mice. Peripheral blood, spleen, and bone marrow were used to measure disease burden. LSC-like cells (GFP⁺Sca-1⁺c-Kit⁺) were determined from total bone marrow and spleen. (A) Confirmation of PPARγ activation with pioglitazone treatment. qPCR expression as fold change in Se-A BCR-ABL splenocytes. Gene expression was normalized to 18S rRNA expression and Se-A vehicle samples were used as control (n = 5). (B) Total WBC (K/μL blood) count in peripheral blood of healthy (n = 4) and BCR-ABL (n = 7) transplanted mice. The shaded box indicates the healthy range. (C) Peripheral blood GFP expressed as percentage of gated input in Se-A BCR-ABL transplanted mice (500 000 events collected, gated on FSC). Representative histogram is shown along with individual data points (n = 6). (D) Representative image and spleen weight in healthy (n = 3-4) and BCR-ABL transplanted (n = 4-7) mice. (E) LSC population evaluation by flow cytometry. LSC population in the spleen (n = 4-6) and bone marrow (n = 4) of BCR-ABL mice. Individual data points are shown from 2 independent experiments. Error bars represent mean ± SEM. *P < .05.